MK2 Inhibition Induces p53-Dependent Senescence in Glioblastoma Cells
Athena F Phoa1, Ariadna Recasens1, Fadi M S Gurgis1
1School of Medical Sciences, Charles Perkins Centre and Faculty of Medicine and Health, The University of Sydney, NSW 2006, Australia.
Abstract:
MAPK-activated protein kinase 2 (MK2) has diverse roles in cancer. In response to chemotherapy, MK2 inhibition is synthetically lethal to p53-deficiency. While TP53 deletion is rare in glioblastomas, these tumors often carry TP53 mutations. Here, we show that MK2 inhibition strongly attenuated glioblastoma cell proliferation through p53wt stabilization and senescence. The senescence-inducing efficacy of MK2 inhibition was particularly strong when cells were co-treated with the standard-of-care temozolomide. However, MK2 inhibition also increased the stability of p53 mutants and enhanced the proliferation of p53-mutant stem cells. These observations reveal that in response to DNA damaging chemotherapy, targeting MK2 in p53-mutated cells produces a phenotype that is distinct from the p53-deficient phenotype. Thus, MK2 represents a novel drug target in 70% glioblastomas harboring intact TP53 gene. However, targeting MK2 in tumors with TP53 mutations may accelerate disease progression. These findings are highly relevant since TP53 mutations occur in over 50% of all cancers.
Insights
MAPK-activated protein kinase 2 (MK2) inhibition halts glioblastoma growth by stabilizing wild-type p53 and inducing senescence. However, it may accelerate progression in p53-mutant glioblastomas, highlighting MK2 as a selective therapeutic target.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Genetics
Background:
- MAPK-activated protein kinase 2 (MK2) plays varied roles in cancer.
- MK2 inhibition shows synthetic lethality in p53-deficient cancers upon chemotherapy.
- Glioblastomas frequently harbor TP53 mutations, though TP53 deletion is rare.
Purpose of the Study:
- To investigate the effect of MK2 inhibition on glioblastoma cell proliferation and senescence.
- To determine the impact of MK2 inhibition on both wild-type and mutant p53 glioblastoma cells.
- To evaluate MK2 as a potential drug target in glioblastoma based on TP53 status.
Main Methods:
- Cell proliferation assays.
- p53 stabilization and senescence induction studies.
- Co-treatment with MK2 inhibitors and temozolomide.
Main Results:
- MK2 inhibition attenuated glioblastoma cell proliferation via p53 wild-type stabilization and senescence.
- Co-treatment with temozolomide enhanced MK2 inhibition's senescence-inducing effect.
- MK2 inhibition increased p53 mutant stability and promoted p53-mutant stem cell proliferation.
Conclusions:
- MK2 inhibition is a promising therapeutic strategy for glioblastomas with intact TP53.
- Targeting MK2 in TP53-mutated glioblastomas may worsen disease progression.
- MK2's distinct effects based on TP53 status offer a selective therapeutic window.
Related Concept Videos
02:23Abnormal Proliferation
01:23Negative Regulator Molecules
02:36DNA Damage can Stall the Cell Cycle
02:36DNA Damage Can Stall the Cell Cycle
02:34Inhibition of Cdk Activity
01:31The Intrinsic Apoptotic Pathway